{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:35:24Z","timestamp":1793140524829,"version":"4.5.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1681\/asn.2014121165","type":"journal-article","created":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T11:05:17Z","timestamp":1433329517000},"page":"120-131","source":"Crossref","is-referenced-by-count":16,"title":["ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor\u2013Induced Thrombotic Microangiopathy"],"prefix":"10.1681","volume":"27","author":[{"given":"Luise","family":"Erpenbeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Demers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna K.","family":"Zsengell\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Gallant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Cifuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac E.","family":"Stillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ananth","family":"Karumanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20230208","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.ki.5001581","article-title":"A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.","volume":"70","author":"Besbas","year":"2006","journal-title":"Kidney Int"},{"key":"R2-17-20230208","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2013.11.004","article-title":"Thrombotic microangiopathies.","volume":"43","author":"Rosove","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"R3-17-20230208","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1161\/CIRCULATIONAHA.109.853127","article-title":"Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.","volume":"123","author":"Powe","year":"2011","journal-title":"Circulation"},{"key":"R4-17-20230208","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2393-9-8","article-title":"The HELLP syndrome: clinical issues and management. A Review.","volume":"9","author":"Haram","year":"2009","journal-title":"BMC Pregnancy Childbirth"},{"key":"R5-17-20230208","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2002-02-0344","article-title":"Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.","volume":"100","author":"Bianchi","year":"2002","journal-title":"Blood"},{"key":"R6-17-20230208","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1053\/beha.2001.0142","article-title":"Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.","volume":"14","author":"Furlan","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"R7-17-20230208","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1538-7836.2005.01425.x","article-title":"Thrombotic thrombocytopenic purpura.","volume":"3","author":"L\u00e4mmle","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R8-17-20230208","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","article-title":"ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.","volume":"100","author":"Dong","year":"2002","journal-title":"Blood"},{"key":"R9-17-20230208","doi-asserted-by":"crossref","first-page":"310596","DOI":"10.5402\/2012\/310596","article-title":"Thrombotic microangiopathies.","volume":"2012","author":"Radhi","year":"2012","journal-title":"ISRN Hematol"},{"key":"R10-17-20230208","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","article-title":"Thrombotic microangiopathy with targeted cancer agents.","volume":"17","author":"Blake-Haskins","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R11-17-20230208","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1179\/1607845412Y.0000000070","article-title":"Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia.","volume":"18","author":"Aref","year":"2013","journal-title":"Hematology"},{"key":"R12-17-20230208","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1067\/mpd.2003.79","article-title":"Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.","volume":"142","author":"Veyradier","year":"2003","journal-title":"J Pediatr"},{"key":"R13-17-20230208","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R14-17-20230208","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/JCO.2008.19.0108","article-title":"Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.","volume":"27","author":"Feldman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R15-17-20230208","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.","volume":"24","author":"Boll\u00e9e","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R16-17-20230208","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s12094-010-0550-4","article-title":"Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?","volume":"12","author":"Jin","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"R17-17-20230208","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy.","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"R18-17-20230208","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/1078-0432.CCR-09-2103","article-title":"Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.","volume":"16","author":"Tew","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R19-17-20230208","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All anti-vascular endothelial growth factor drugs can induce \u2018pre-eclampsia-like syndrome\u2019: a RARe study.","volume":"29","author":"Vigneau","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R20-17-20230208","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R21-17-20230208","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"R22-17-20230208","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia.","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"key":"R23-17-20230208","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/j.1582-4934.2009.00820.x","article-title":"Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.","volume":"14","author":"Bergmann","year":"2010","journal-title":"J Cell Mol Med"},{"key":"R24-17-20230208","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/HYPERTENSIONAHA.107.092098","article-title":"Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.","volume":"50","author":"Li","year":"2007","journal-title":"Hypertension"},{"key":"R25-17-20230208","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1073\/pnas.081615298","article-title":"Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.","volume":"98","author":"Kuo","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-17-20230208","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1182\/blood-2010-09-303438","article-title":"VWF self-association: more bands for the buck.","volume":"116","author":"L\u00f3pez","year":"2010","journal-title":"Blood"},{"key":"R27-17-20230208","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1172\/JCI26007","article-title":"Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.","volume":"115","author":"Motto","year":"2005","journal-title":"J Clin Invest"},{"key":"R28-17-20230208","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","article-title":"A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.","volume":"119","author":"Schiviz","year":"2012","journal-title":"Blood"},{"key":"R29-17-20230208","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1681\/ASN.2011040369","article-title":"eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype.","volume":"23","author":"Li","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R30-17-20230208","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer.","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"R31-17-20230208","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1681\/ASN.2007020255","article-title":"The glomerular injury of preeclampsia.","volume":"18","author":"Stillman","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R32-17-20230208","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2013-07-514992","article-title":"VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia\/reperfusion injury in mice.","volume":"123","author":"Savchenko","year":"2014","journal-title":"Blood"},{"key":"R33-17-20230208","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijgo.2008.09.014","article-title":"Maternal deaths due to eclampsia and HELLP syndrome.","volume":"104","author":"Vigil-De Gracia","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"R34-17-20230208","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity.","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"R35-17-20230208","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.","volume":"8","author":"Frangi\u00e9","year":"2007","journal-title":"Lancet Oncol"},{"key":"R36-17-20230208","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/ki.2008.256","article-title":"Glomerular disease related to anti-VEGF therapy.","volume":"74","author":"Stokes","year":"2008","journal-title":"Kidney Int"},{"key":"R37-17-20230208","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1681\/ASN.2005080810","article-title":"Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.","volume":"17","author":"Eremina","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R38-17-20230208","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jth.12255","article-title":"Animal models for thrombotic thrombocytopenic purpura.","volume":"11","author":"Vanhoorelbeke","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R39-17-20230208","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2005-07-2765","article-title":"Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura.","volume":"107","author":"Banno","year":"2006","journal-title":"Blood"},{"key":"R40-17-20230208","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2013-10-531392","article-title":"Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice.","volume":"123","author":"Morioka","year":"2014","journal-title":"Blood"},{"key":"R41-17-20230208","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2141.2008.07515.x","article-title":"Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients.","volume":"144","author":"Fujimura","year":"2009","journal-title":"Br J Haematol"},{"key":"R42-17-20230208","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/ATVBAHA.109.186742","article-title":"Inhibition of VEGF or TGF-beta signaling activates endothelium and increases leukocyte rolling.","volume":"29","author":"Walshe","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R43-17-20230208","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1681\/ASN.2009010061","article-title":"The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD.","volume":"20","author":"Di Marco","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R44-17-20230208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"key":"R45-17-20230208","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/jid.2013.292","article-title":"Blocking von Willebrand factor for treatment of cutaneous inflammation.","volume":"134","author":"Hillgruber","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R46-17-20230208","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1084\/jem.20080130","article-title":"ADAMTS13: a new link between thrombosis and inflammation.","volume":"205","author":"Chauhan","year":"2008","journal-title":"J Exp Med"},{"key":"R47-17-20230208","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1182\/blood-2009-03-213264","article-title":"von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.","volume":"114","author":"Zhao","year":"2009","journal-title":"Blood"},{"key":"R48-17-20230208","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2011-09-376202","article-title":"ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice.","volume":"119","author":"Gandhi","year":"2012","journal-title":"Blood"},{"key":"R49-17-20230208","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.blre.2005.02.001","article-title":"Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment.","volume":"20","author":"Murrin","year":"2006","journal-title":"Blood Rev"},{"key":"R50-17-20230208","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.3324\/haematol.2013.100685","article-title":"Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.","volume":"99","author":"Grillberger","year":"2014","journal-title":"Haematologica"},{"key":"R51-17-20230208","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"key":"R52-17-20230208","first-page":"2244","article-title":"Deficient activity of von Willebrand\u2019s factor-cleaving protease in patients with disseminated malignancies.","volume":"59","author":"Oleksowicz","year":"1999","journal-title":"Cancer Res"},{"key":"R53-17-20230208","first-page":"454","article-title":"Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease).","volume":"88","author":"Mannucci","year":"2003","journal-title":"Haematologica"},{"key":"R54-17-20230208","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/ATVBAHA.111.223610","article-title":"Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology.","volume":"31","author":"Stepanian","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R55-17-20230208","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3109\/10428194.2011.580474","article-title":"Acquired immune-mediated thrombophilia in lymphoproliferative disorders.","volume":"52","author":"Lechner","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R56-17-20230208","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5414\/CN107579","article-title":"Thrombotic thrombocytopenic purpura due to anti-ADAMTS13 antibodies in multiple myeloma.","volume":"81","author":"Yao","year":"2014","journal-title":"Clin Nephrol"},{"key":"R57-17-20230208","first-page":"467","article-title":"Pre-eclampsia: pathophysiology, diagnosis, and management.","volume":"7","author":"Uzan","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"R58-17-20230208","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies.","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"key":"R60-17-20230208","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1160\/TH11-02-0069","article-title":"A dose ranging phase I\/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.","volume":"106","author":"Jilma-Stohlawetz","year":"2011","journal-title":"Thromb Haemost"},{"key":"R61-17-20230208","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1182\/blood-2012-04-421248","article-title":"Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.","volume":"120","author":"Feys","year":"2012","journal-title":"Blood"},{"key":"R62-17-20230208","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice.","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"},{"key":"R63-17-20230208","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/trf.12440","article-title":"Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report.","volume":"54","author":"Li","year":"2014","journal-title":"Transfusion"},{"key":"R64-17-20230208","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2007-08-108571","article-title":"The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis.","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"key":"R65-17-20230208","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1751-553X.2011.01380.x","article-title":"ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes.","volume":"34","author":"Zini","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"R66-17-20230208","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ajh.2008.301","article-title":"Validation of volume-pressure recording tail-cuff blood pressure measurements.","volume":"21","author":"Feng","year":"2008","journal-title":"Am J Hypertens"},{"key":"R67-17-20230208","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/01.HYP.25.5.1111","article-title":"A noninvasive computerized tail-cuff system for measuring blood pressure in mice.","volume":"25","author":"Krege","year":"1995","journal-title":"Hypertension"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201601000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:26:38Z","timestamp":1786130798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201601000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2014121165","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}